Novartis scientists, in collaboration with an international team of researchers from the University of California, San Diego, and Columbia University, have identified a novel drug target for treating malaria, a scourge of many tropical Third World countries.
In a discovery that could put a vaccine for hepatitis C closer in sight, researchers have been able to characterize a key protein in the virus that aids infection in the liver.
Writing in a recent issue of Nature, Dr. Benjamin Haibe-Kains of the Institut de Recherches Cliniques de Montréal says that additional standardization to improve the reproducibility of drug screening studies is needed.
The Obama administration announced Monday afternoon that the National Institutes of Health will redirect $100 million in funding to establish a new program to find better treatments--and eventually, a cure--for HIV and AIDS.
The environment that exists inside a person's intestines may impact the effectiveness of cancer therapy, according to new research by investigators at the National Cancer Institute and France's Gustave Roussy Institute.
In an effort to better understand diseases that have long eluded diagnosis, the New York Stem Cell Foundation Research Institute is partnering with the National Institutes of Health's Undiagnosed Diseases Program to create cell models of rare medical conditions.
Using RNA interference technology, scientists have discovered a network of genes that could serve as new therapeutic targets for Parkinson's disease as well as other diseases characterized by mitochondrial damage.
Amidst a challenging R&D environment, Atlanta-based Biota Pharmaceuticals has dumped its preclinical antibiotics program, saying that it will continue to seek out licensing agreements and other deals to advance the development of its candidates.
Eli Lilly and the nonprofit Project A.L.S. are teaming up to boost the pipeline of potential drugs for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig' disease.
A DNA vaccine developed by Blue Bell, PA-based Inovio Pharmaceuticals induced robust and durable immune responses against the deadly MERS coronavirus in a preclinical model.
Austrian researchers have discovered a compound that may be able to activate a protein in the body to trigger fat burning.
The antidote for Alzheimer's may be hidden in two common herbs. A study conducted at Saint Louis University found that enhanced extracts derived from antioxidants in spearmint and rosemary improved learning and memory in mice.
Investigators at MIT may have found the key to designing the next generation of antibiotics--a toxin called SocAB that blocks DNA replication and inhibits bacterial growth.
Three-dimensional kidney structures created for the first time in a laboratory by scientists at the Salk Institute for Biological Studies could provide a new possibility for developing drugs that treat kidney disease and restore kidney function.
Oxford University scientists are teaming up with London-based MRC Technology, a tech transfer nonprofit, to screen selective and potent potassium channel activators that could be formulated into new therapies for migraine relief.
Canada's Tekmira Pharmaceuticals ($TKMR) has unveiled new data showing that its antiviral RNA interference therapeutics were effective at abolishing Ebola and Marburg viruses in preclinical studies when treatment was delayed.
A cellular pathway interaction that plays a role in repairing serious injuries may also be a promising target for preventing the spread of a deadly type of brain cancer, according to a new study.
By targeting a family of proteins on the surface of certain cells, scientists have been able to halt and reverse tissue scarring in liver, kidneys and lungs in mice.
Boehringer Ingelheim has chosen an antibody therapeutic candidate discovered by Rockville, MD-based MacroGenics for preclinical development.
The White House's Office of Management and Budget released a new report that sheds light on how the 16-day federal government shutdown in October impacted scientific research.